Download

Audience for the document: Share Class: Language of the document:

Download

Share Class: Language of the document:

Change Details

If you need to change your email address please contact us.
Subscriptions
OK
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the twenty four-year period ended June 30, 2020, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest

Please enter valid search characters

Expanding Opportunities in China

October 2021 / EMERGING MARKETS

China: Too Big to Ignore

China: Too Big to Ignore

China: Too Big to Ignore

Insights Webinar Summary

By Christopher J. Kushlis & Wenli Zheng

By Christopher J. Kushlis & Wenli Zheng

September 2021 / FIXED INCOME

Controlled Deflation of the China Property...

Controlled Deflation of the China Property Debt Balloon

Controlled Deflation of the China Property...

Beijing’s policy actions in the property sector seem to be containing any potential...

By Sheldon Chan & Anna Zhang

By Sheldon Chan & Anna Zhang

August 2021 / MARKET EVENTS

China Regulation—Opportunity May Lie in the...

China Regulation—Opportunity May Lie in the Midst of Stock Sell-Off

China Regulation—Opportunity May Lie in the...

We are assessing potential winners and losers amid new regulations in the education...

By Multiple Authors

By Multiple Authors

June 2021 / EMERGING MARKETS

Constructing a Chinese Equities Portfolio

Constructing a Chinese Equities Portfolio

Constructing a Chinese Equities Portfolio

Seek to exploit market inefficiencies and extract value from entire investment universe.

By Irmak Surenkok

Irmak Surenkok Portfolio Specialist

March 2021 / EMERGING MARKETS

China's Economy: Recovery and Rebalancing

China's Economy: Recovery and Rebalancing

China's Economy: Recovery and Rebalancing

Emerging from the pandemic, an encouraging pathway for China’s economy.

By Christopher J. Kushlis

Christopher J. Kushlis Asia Sovereign Analyst, London

November 2020 / STRATEGY

T. Rowe Price Strategy Focus on China Evolutio...

T. Rowe Price Strategy Focus on China Evolution Equity

T. Rowe Price Strategy Focus on China Evolution...

By Wenli Zheng

Wenli Zheng Regional Portfolio Manager

China Evolution Equity Strategy

The strategy seeks to identify mispriced companies with opportunities driven by change. We scour the full spectrum of Chinese equity markets—A-shares, H-shares, and U.S. Listed ADRs—in pursuit of the most compelling risk/reward prospects.

China Evolution Equity Strategy Focus

China Evolution Equity Composite Strategy Highlight

September 2021 / FIXED INCOME

Regulatory Actions in China: Short-Term Pain,...

Regulatory Actions in China: Short-Term Pain, Long-Term Gain

Regulatory Actions in China: Short-Term Pain,...

Beijing’s tightening grip bodes well for China Inc.'s health.

By Sheldon Chan, Christopher J. Kushlis & Lee Sun

By Sheldon Chan, Christopher J. Kushlis & Lee Sun

June 2021 / INTERNATIONAL EQUITIES

Gains Still to Be Found in Chinese Equities

Gains Still to Be Found in Chinese Equities

Gains Still to Be Found in Chinese Equities

Corporate earnings will likely be the focus after a post‑pandemic recovery.

By Wenli Zheng

Wenli Zheng Regional Portfolio Manager

May 2021 / EMERGING MARKETS

What's Next for China's Geopolitical Relations...

What's Next for China's Geopolitical Relations?

What's Next for China's Geopolitical Relations?

Tensions remain elevated, but expect a return to more multilateral negotiations.

By Katie Elizabeth Deal & Christopher J. Kushlis

By Katie Elizabeth Deal & Christopher J. Kushlis